A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 411-414, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-8775
ABSTRACT
Paragangliomas are relatively rare chromaffin cell tumors which may be cured through resection. Patients with paragangliomas may develop metastatic diseases. There is no consensus regarding refractory chemotherapy for treatment of metastatic disease. In this report, we presented a case of a 43-year-old woman who was admitted to the hospital with a history of episodic headaches, diaphoresis, and weakness. Elevated plasma catecholamine levels and a right paraaortic mass were observed on computed tomography. The mass was excised, and a diagnosis of paraganglioma was confirmed. After 20 months of follow-up, local recurrence and metastases were detected in the thorax, abdomen, and skeletal system. Plasma and urinary catecholamine levels were high. Chemotherapy was administered, and no improvement was observed. Therefore, following this palliative conventional chemotherapy, sorafenib was administered for three months, and, finally, positron emission tomography showed that the patient's lesions had completely regressed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Paraganglioma
/
Feocromocitoma
/
Plasma
/
Recurrencia
/
Tórax
/
Estudios de Seguimiento
/
Paraganglioma Extraadrenal
/
Células Cromafines
/
Consenso
/
Tomografía de Emisión de Positrones
Tipo de estudio:
Estudio diagnóstico
/
Guía de Práctica Clínica
/
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Adulto
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Cancer Research and Treatment
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS